Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis.

Kamrul-Hasan ABM, Selim S, Afsana F, Nagendra L, Ahmed R, Dutta D

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists11 Dec 2024Cited by 1 (Europe PMC)

PMID39672540DOI10.1016/j.eprac.2024.12.005PepBankPUB-39672540

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes inadequately controlled on oral drugs, tirzepatide 5 mg reduced HbA1c by 0.89% more than basal insulins.
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c more than basal insulin.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline, tirzepatide 5 mg
Study
n = 4,339
Comparator
Basal insulin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
HbA1c mean difference
−0.89%
tirzepatide 5 mg vs basal insulin
Source sentences
Summary
Compared to basal insulins, tirzepatide arms achieved greater reductions from the baseline in HbA1c (tirzepatide 5 mg: mean difference (MD) -0.89% [95% CI: -1.23, -0.54]; tirzepatide 10 mg: MD -1.11% [95% CI: -1.42, -0.79]; and tirzepatide 15 mg: MD -1.23% [95% CI: -1.48, -0.97]; P < .00001 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254001
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes inadequately controlled on oral drugs, tirzepatide 10 mg reduced HbA1c by 1.11% more than basal insulins.
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c more than basal insulin.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline, tirzepatide 10 mg
Study
n = 4,339
Comparator
Basal insulin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
HbA1c mean difference
−1.11%
tirzepatide 10 mg vs basal insulin
Source sentences
Summary
Compared to basal insulins, tirzepatide arms achieved greater reductions from the baseline in HbA1c (tirzepatide 5 mg: mean difference (MD) -0.89% [95% CI: -1.23, -0.54]; tirzepatide 10 mg: MD -1.11% [95% CI: -1.42, -0.79]; and tirzepatide 15 mg: MD -1.23% [95% CI: -1.48, -0.97]; P < .00001 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254002
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes inadequately controlled on oral drugs, tirzepatide 15 mg reduced HbA1c by 1.23% more than basal insulins.
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than basal insulin.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change from baseline, tirzepatide 15 mg
Study
n = 4,339
Comparator
Basal insulin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
HbA1c mean difference
−1.23%
tirzepatide 15 mg vs basal insulin
Source sentences
Summary
Compared to basal insulins, tirzepatide arms achieved greater reductions from the baseline in HbA1c (tirzepatide 5 mg: mean difference (MD) -0.89% [95% CI: -1.23, -0.54]; tirzepatide 10 mg: MD -1.11% [95% CI: -1.42, -0.79]; and tirzepatide 15 mg: MD -1.23% [95% CI: -1.48, -0.97]; P < .00001 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254003
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, more patients on tirzepatide than on basal insulin reached HbA1c below 7.0%.
In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on basal insulin reached an HbA1c below 7.0%.
Peptide
Tirzepatide
Outcome
IncreaseProportion with HbA1c below 7.0%
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Additionally, the proportions of patients achieving HbA1c levels below 7.0%, 6.5%, and 5.7% were significantly greater in the tirzepatide groups than in the basal insulin group.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254004
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, more patients on tirzepatide than on basal insulin reached HbA1c below 6.5%.
In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on basal insulin reached an HbA1c below 6.5%.
Peptide
Tirzepatide
Outcome
IncreaseProportion with HbA1c below 6.5%
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Additionally, the proportions of patients achieving HbA1c levels below 7.0%, 6.5%, and 5.7% were significantly greater in the tirzepatide groups than in the basal insulin group.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254005
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, more patients on tirzepatide than on basal insulin reached HbA1c below 5.7%.
In plain wordsIn adults with type 2 diabetes, more people on tirzepatide than on basal insulin reached an HbA1c below 5.7%.
Peptide
Tirzepatide
Outcome
IncreaseProportion with HbA1c below 5.7%
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Additionally, the proportions of patients achieving HbA1c levels below 7.0%, 6.5%, and 5.7% were significantly greater in the tirzepatide groups than in the basal insulin group.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254006
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide gave greater body weight reductions than basal insulins.
In plain wordsIn adults with type 2 diabetes, tirzepatide lowered body weight more than basal insulin did.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Greater body weight and blood pressure reductions were observed with tirzepatide than with basal insulins
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254007
08HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide gave greater blood pressure reductions than basal insulins.
In plain wordsIn adults with type 2 diabetes, tirzepatide lowered blood pressure more than basal insulin did.
Peptide
Tirzepatide
Outcome
DecreaseBlood pressure reduction
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Greater body weight and blood pressure reductions were observed with tirzepatide than with basal insulins.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254008
09HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide had a more favorable impact on lipid profile than basal insulins.
In plain wordsIn adults with type 2 diabetes, tirzepatide had a more favorable effect on blood fats than basal insulin.
Peptide
Tirzepatide
Outcome
Not applicableLipid profile
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Moreover, tirzepatide had a more favorable impact on lipid profile.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254009
10HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, hypoglycemia was less frequent with tirzepatide than with basal insulins.
In plain wordsIn adults with type 2 diabetes, low blood sugar events were less frequent with tirzepatide than with basal insulin.
Peptide
Tirzepatide
Outcome
DecreaseHypoglycemia
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Hypoglycemia was less frequent with tirzepatide.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254010
11HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, gastrointestinal adverse events were more frequent with tirzepatide (all doses) than with basal insulin.
In plain wordsIn adults with type 2 diabetes, stomach and bowel side effects were more frequent with tirzepatide than with basal insulin.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
all dosesAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events (AEs) were more frequent with tirzepatide (all doses) than basal insulin
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254011
12HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, serious adverse events were comparable between tirzepatide and basal insulin.
In plain wordsIn adults with type 2 diabetes, serious side effects were similar with tirzepatide and basal insulin.
Peptide
Tirzepatide
Outcome
No significant changeSerious adverse events
Study
n = 4,339
Comparator
Basal insulin
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
although serious AEs were comparable between the 2 groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trials involving subjects with T2D inadequately controlled with oral anti-hyperglycemic drugs and receiving tirzepatide in intervention arm and basal insulins in control arm as add-on therapy were searched throughout the electronic databases.
Summary · context
Three randomized controlled trials involving 4339 subjects met the inclusion criteria.
Report a problemFND-3967254012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.